- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Interventions
- Hypofractionated Radiation Therapy
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 231
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
- Interventions
- Investigational Imaging device, AVB-620
- Device · Drug
- Lead sponsor
- Avelas Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 29
- States / cities
- Berkeley, California • Duarte, California • Irvine, California + 22 more
- Conditions
- Breast Cancer, Ductal Carcinoma in Situ
- Interventions
- Mammosite ML
- Device
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Ductal Breast Carcinoma In Situ, Postmenopausal
- Interventions
- Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 79 Years · Female only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Chicago, Illinois • Geneva, Illinois + 7 more
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
- Interventions
- Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy
- Drug · Procedure
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 4
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Interventions
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
- Procedure · Other · Genetic + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
- Conditions
- Breast Cancer
- Interventions
- AVB-620
- Drug
- Lead sponsor
- Avelas Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma in Situ
- Interventions
- Patient Navigation, Questionnaire
- Behavioral · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- omega-3 fatty acid, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Breast Cancer
- Interventions
- celecoxib, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 9
- States / cities
- Glendale, California • Albuquerque, New Mexico • Houston, Texas + 1 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, exemestane, letrozole, assessment of therapy complications
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 80 Years · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- 3-dimensional conformal accelerated partial breast irradiation
- Radiation
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- HER-2 pulsed DC1, trastuzumab, pertuzumab
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Polyphenon E
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 4
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
- Conditions
- Ductal Breast Carcinoma In Situ, HER2/Neu Positive
- Interventions
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Houston, Texas
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms
- Interventions
- conjugated estrogens, medroxyprogesterone
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Breast Cancer
- Interventions
- Breast Brachytherapy with Mammosite RTS, Intensity Modulated Radiotherapy
- Radiation
- Lead sponsor
- Rocky Mountain Cancer Centers
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 3 more
- Conditions
- Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
- Interventions
- Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • New York, New York
- Conditions
- Breast Carcinoma
- Interventions
- Tamoxifen, Fulvestrant
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California